EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Selective Anti-Herpesvirus Agents

Erik De Clercq

Antiviral Chemistry and Chemotherapy · 2013-06 · 23 (3) · 93-101

DOI: 10.3851/imp2533 ↗

At a glance

Übersichtsarbeit in Antiviral Chemistry and Chemotherapy, published online on 2013-06-01. Written by Erik De Clercq. Institution: Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. erik.declercq@rega.kuleuven.be. Cited 78 times so far (Crossref); 63 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

This review article focuses on the anti-herpesvirus agents effective against herpes simplex virus, varicella-zoster virus and cytomegalovirus, which have either been licensed for clinical use (idoxuridine, trifluridine, brivudin, acyclovir, valaciclovir, valganciclovir, famciclovir and foscarnet) or are under clinical development (CMX001 [the hexadecyloxypropyl prodrug of cidofovir], the helicase-primase inhibitor BAY 57–1293 [now referred to as AIC316], FV-100 [the valine ester of Cf 1743] and the terminase inhibitor letermovir [AIC246]).

Subjects

MeSH terms (MEDLINE)

AnimalsAntiviral AgentsCytomegalovirusHerpesviridae InfectionsHerpesvirus 3, HumanHumansSimplexvirus

Substances

Antiviral Agents

Authors and institutions

  • Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. erik.declercq@rega.kuleuven.be.

Cite

APA

De Clercq, E. (2013). Selective Anti-Herpesvirus Agents. Antiviral Chemistry and Chemotherapy, 23(3), 93-101. https://doi.org/10.3851/imp2533

Vancouver

De Clercq E. Selective Anti-Herpesvirus Agents. Antiviral Chemistry and Chemotherapy. 2013;23(3):93-101. doi:10.3851/imp2533

BibTeX
@article{DeClercq2013,
  author = {De Clercq, Erik},
  title = {Selective Anti-Herpesvirus Agents},
  journal = {Antiviral Chemistry and Chemotherapy},
  year = {2013},
  volume = {23},
  number = {3},
  pages = {93--101},
  doi = {10.3851/imp2533}
}
Start for free →